戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 echanism for virus-induced susceptibility to bacterial superinfection.
2 e practitioners, allowing the propagation of bacterial superinfection.
3 distinguish between patients with or without bacterial superinfection.
4  However, clinicians have few tools to treat bacterial superinfection.
5 onsiderable morbidity from viral disease and bacterial superinfection.
6 potential in a model of viral infection with bacterial superinfection.
7 eases disease severity and susceptibility to bacterial superinfections.
8 ier damage, causing susceptibility to lethal bacterial superinfections.
9  IL-23 release, increasing susceptibility to bacterial superinfections.
10 ches to restore lung innate immunity against bacterial superinfections.
11 clinical management for influenza-associated bacterial superinfections.
12 d 14.3% of patients, respectively; 12.5% had bacterial superinfections.
13  understand the role of immune memory during bacterial superinfections.
14 ng to enhanced susceptibility to respiratory bacterial superinfections.
15 lung inflammation and were less sensitive to bacterial superinfection after infection with influenza
16                                              Bacterial superinfection and associated lung immunopatho
17 phic pneumonia, requirement for ventilation, bacterial superinfection, and elevated urea level and wh
18                                              Bacterial superinfections are a major cause of morbidity
19 ence for influenza viruses in the setting of bacterial superinfection, are broadly associated with en
20  to determine the prevalence and etiology of bacterial superinfection at the time of initial intubati
21  pneumonia requiring mechanical ventilation, bacterial superinfection at the time of intubation occur
22                Current therapy for influenza/bacterial superinfection consists of treating the underl
23  inflammatory PB1-F2 phenotype that supports bacterial superinfection during adaptation of H3N2 virus
24                         Influenza-associated bacterial superinfections have devastating impacts on th
25 ude lubrication and prevention/management of bacterial superinfection in monkeypox keratitis.
26  use machine learning to predict the risk of bacterial superinfection in SARS-CoV-2-positive individu
27            Here we describe a mouse model of bacterial superinfection in which a mild, self-limiting
28 bacteria and discover novel modes to prevent bacterial superinfections in the lungs of persons with i
29 iated with an elevated risk of succumbing to bacterial superinfection, is also seen in the aftermath
30 nfluenza such as increased susceptibility to bacterial superinfection, may be mitigated in allergic h
31                                 In the mouse bacterial superinfection model, both peptide and virus w
32 luenza virus infection result from secondary bacterial superinfection, most commonly caused by Strept
33 inflammatory responses to IAV in vivo and of bacterial superinfection of IAV-infected subjects.
34 viduals were hospitalised, predominantly for bacterial superinfection of lesions and pain management.
35  receive empirical antibiotics for suspected bacterial superinfection on the basis of weak evidence.
36 mber of influenza-related deaths result from bacterial superinfections, particularly secondary pneumo
37                          In the absence of a bacterial superinfection, prescribing antibacterial ther
38 l outcome and lung immunopathology caused by bacterial superinfection requires the control of both ba
39 ory syncytial virus (RSV) bronchiolitis with bacterial superinfection secondary to administration of
40 uenza A virus (IAV) infection and during the bacterial superinfections that are a significant cause o
41        To test the role of Nrf2 during viral-bacterial superinfection, we used a mouse model of influ
42        A common complication of influenza is bacterial superinfection, which exacerbates morbidity an
43   However, only patients with AD suffer from bacterial superinfections with this pathogen, which impl
44 as emerged as the dominant pathogen found in bacterial superinfection, with Streptococcus pneumoniae
45                                              Bacterial superinfection within 48 hours of intubation w